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S U M M A R Y
Background: Anemia, neutropenia, and thrombocytopenia are commonly observed in HIV-infected
patients. This study was undertaken to evaluate the prevalence of cytopenias and their association with
CD4 count. Furthermore, the association of hemoglobin concentration with mortality was also
investigated.
Methods: We reviewed the data of 701 HIV-infected patients followed at our institution. Blood cell
counts, hemoglobin concentration, CD4 count, and viral load were recorded. We also recorded the
mortality rate after 1 year in the groups with CD4 <200/ml and 200/ml according to hemoglobin
concentration.
Results: Of the total patients, 37.5% had anemia; 61.1% (110/180) were in the low CD4 group and 29.4%
(153/521) were in the high CD4 group (p < 0.01). Mean neutrophil counts were 2.610  109/l and
3.204  109/l in the low CD4 and high CD4 groups, respectively (p < 0.01); mean platelet counts were
218.639  109/l and 234.807  109/l for the low CD4 and the high CD4 groups, respectively (p = 0.03).
Patients whose hemoglobin concentration was below the median value had a higher death rate in both
the low CD4 (14 vs. 4 deaths, p = 0.013) and high CD4 (8 vs. 1 death, p = 0.0158) groups.
Conclusions: We found an association between CD4 count and hemoglobin level, neutrophil count, and
platelet count, and that anemia was independently associated with a higher mortality.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The most important biomarkers of disease stage and progres-
sion in patients with an HIV infection are the CD4 count and HIV
RNA concentration.1–3 However, there are other factors that can
inﬂuence or predict the prognosis.4 Hematological abnormalities,
such as anemia, neutropenia, and thrombocytopenia, are com-
monly observed in patients infected with HIV.5,6 For this reason the
total lymphocyte count, white blood cell count, and hematocrit or
hemoglobin concentration have been proposed as alternative
markers of the disease, especially for developing countries where
ﬁnancial resources are limited.7 Nevertheless, the majority of these
markers have not been adopted into routine use because of their
supposedly poor correlation with disease progression.
Anemia is the most frequent hematological abnormality in
patients infected with HIV, even in patients under highly active
antiretroviral therapy (HAART), and has been associated with* Corresponding author. Tel.: +55 16 21019300; fax: +55 16 21019309.
E-mail address: gil@hemocentro.fmrp.usp.br (G.C. De Santis).
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doi:10.1016/j.ijid.2011.08.001impaired quality of life,8–10 accelerated progression of the disease,
and a higher mortality rate.11–15 Usually, anemia in an HIV-
infected patient is normocytic and normochromic and is associated
with a low reticulocyte count.16 The causes of anemia are various.
Its pathophysiology involves three mechanisms: (1) decreased red
blood cell (RBC) production: opportunistic infection, direct effect
of HIV infection itself, myelosuppressive medications, decreased
production of erythropoietin, hypogonadism; (2) increased RBC
destruction: autoimmune hemolytic anemia, thrombotic micro-
angiopathy, disseminated intravascular coagulation; and (3)
ineffective RBC production: folic acid and vitamin B12 deﬁciencies.
Nutritional deﬁciencies such as vitamin and iron deﬁciencies are
common in developing countries.17 The degree of inﬂammation
and its impact on hemoglobin levels could eventually be useful as a
marker of disease status and prognosis.
Neutropenia as well as anemia is commonly observed in
patients with HIV infection. Up to 70% of patients at advanced
stages of AIDS present low neutrophil counts.16 Worsening
HIV disease, demonstrated by decreasing CD4 cells counts
and increasing HIV-1 RNA levels, has been associated with
the development of neutropenia.18 Thrombocytopenia affectsses. Published by Elsevier Ltd. All rights reserved.
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course of their illness, and low platelet counts can be the only
hematological abnormality at presentation.6 Isolated thrombo-
cytopenia does not seem to affect the prognosis.19,20
The objective of this cross-sectional retrospective study was
to evaluate the frequency of hematological abnormalities in HIV
patients, and to evaluate the correlation of anemia, neutropenia,
and thrombocytopenia with CD4 cell number, viral load, and
with mortality. Furthermore, we aimed to evaluate the impact of
zidovudine (ZDV) on hemoglobin concentration levels.
2. Methods
2.1. Patient population
We reviewed the data of 701 consecutive HIV-infected
outpatients followed at our institution (Hospital das Clinicas de
Ribeira˜o Preto da Universidade de Sa˜o Paulo-USP) between August
and November 2009. Patients had to have had at least one
determination of hemoglobin level, CD4 count, and viral load
(Table 1). We also recorded the number of deaths 1 year later.
Patients under 16 were excluded from the analysis. We deﬁned
anemia as a hemoglobin concentration below 12.0 g/dl for women
and below 14.0 g/dl for men. Data regarding co-infection with
hepatitis C virus (HCV) were also recorded.
This study was carried out in accordance with the Helsinki
Declaration of 1975, as revised in 2000, and was approved by the
ethics committee of our institution (protocol number 13 418/
2009). As this was a retrospective and cross-sectional analysis, the
local committee exempted the authors from the need to apply for
informed consent.
2.2. Blood cell counts
Peripheral blood cell counts were performed using an ABX
Pentra 120 DX automated hematology analyzer (Horiba ABX,
Montpellier, France). The analyses recorded were RBC count,
hemoglobin concentration, hematocrit, mean corpuscular volume
(MCV), and white blood cell (WBC), lymphocyte, neutrophil, and
platelet counts.Table 1
Description of the patient population
Variables Valuea
Gender
Male 432 (61.6%)
Female 269 (38.4%)
Age (years) 42 (16–79)
Exposure group
Injection drug use 104 (14.8%)
Male homosexual 92 (13.1%)
Heterosexual 425 (60.6%)
Blood transfusion 21 (3.0%)
Maternal–fetal transmission 3 (0.4%)
Not deﬁned 56 (8.0%)
Regular use of HAART 577 (82.3%)
CD4
CD4 200/ml 521 (74.3%)
CD4 <200/ml 180 (25.7%)
Undetectable viral load 458 (65.3%)
Hemoglobin (g/dl)
Male 14.4 (6.4–20)
Female 12.6 (6.4–15.9)
Neutrophil count ( 109/l) 2.800 (4.00–17.500)
Platelet count ( 109/l) 227.000 (16.000–615.000)
HAART, highly active antiretroviral therapy.
a Values are n (%) or mean (range).2.3. CD4 quantiﬁcation
Absolute CD4 counts were obtained from a combination of the
results from the hematology analyzer and from ﬂow cytometry
on a BD FACSCalibur cytometer (Becton Dickinson, San Jose, CA,
USA). The reagents employed were the BD Multitest CD3/CD4/
CD8/CD45 (Becton Dickinson, San Jose, CA, USA). In brief,
specimens were stained for 15 min at room temperature with
a cocktail of four monoclonal antibodies (CD4APC, CD8PE,
CD45PerCP, CD3FITC). Erythrocytes were lysed by incubating
with lysing solution (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA) for 15 min at room temperature at a ratio of 1:9 (volume of
sample:volume of lysing solution), and the specimens were
analyzed. When combined with total lymphocyte counts from
the hematology analyzer, the ﬂow cytometric analyses produced
T-cell CD4 counts.
2.4. HIV-1 viral load determination
HIV viral load was determined directly by a hybridization
sandwich nucleic acid technique using the VERSANT1 HIV-1 RNA
3.0 (bDNA) (Siemens Healthcare Diagnostics Inc., Tarrytown, NY,
USA) protocol according to the manufacturer’s instructions. Values
less than 50 copies/ml were reported as undetectable. A negative
control was included in each run.
2.5. Statistical analyses
Statistical analyses were performed using SAS version 9.1 (SAS
Institute Inc., Cary, NC, USA). Basic demographic characteristics of
the study population were obtained, and comparisons were made
between groups using unpaired t-tests, W2 tests, and Wilcoxon
rank sum tests, as appropriate. Comparison of categorical variables
(clinical features or events) was performed using Fisher’s exact
test. Correlations between each hematological variable with viral
load were tested using the Pearson correlation coefﬁcient. The
comparison of hemoglobin results according to gender was done
using one-way analysis of variance (ANOVA). A p-value of less than
0.05 was considered signiﬁcant.
3. Results
3.1. Groups according to CD4 number
The patients were divided into two groups according to their
CD4 count: low CD4 (<200/ml) and high CD4 (200/ml). (At ﬁrst,
the patients were divided into three groups according to CD4
count: <200/ml, 200–500/ml, and 500/ml. However, the results of
the hematological variables were not different between the last
two groups, and for this reason they were merged.) The low CD4
group comprised 180 patients (25.7%) and the high CD4 group 521
patients (74.3%). There were no differences between the groups
with regard to the types of antiretroviral drugs used (data not
shown) or the time from diagnosis (CD4 <200/ml: 96  75 months;
CD4 200/ml: 106  61 months).
3.2. Hemoglobin concentration and prevalence of anemia
A total of 37.5% of patients (263/701) had anemia at the
moment of evaluation. The prevalence of anemia was 33.1% (89/
269) in female patients and 40.5% (175/432) in male patients
(p = 0.0544). Furthermore, 61.1% of patients (110/180) had anemia
in the low CD4 group and 29.4% (153/521) in the high CD4 group
(p < 0.01). The mean  standard deviation (SD) hemoglobin con-
centrations were 11.6  2.07 g/dl and 12.8  1.47 g/dl for female
patients in the low and high CD4 cell count groups, respectively
Figure 1. Hemoglobin concentration according to gender and CD4 groups.
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patients in the low and high CD4 cell count groups, respectively
(p < 0.001) (Figure 1). Forty-ﬁve percent (119/263) of the anemic
patients presented an MCV above 100 ﬂ, and 8.4% (22/263) an MCV
below 80 ﬂ. As expected, microcytic anemia was more frequent in
females (15.5% vs. 4.5%; p = 0.0039). There was no difference between
the types of anemia (according to the MCV) in relation to CD4 groups
(data not shown).
3.3. Neutrophil and platelet counts in the low and high CD4 cell groups
The mean  SD neutrophil counts were 2.610  1.331  109/l and
3.204  1.690  109/l for the low CD4 and high CD4 groups,
respectively (p < 0.01) (Figure 2A).
The mean  SD platelet counts were 218.639  110.291  109/l
and 234.807  79.080  109/l for the low CD4 and the high CD4
groups, respectively (p = 0.03) (Figure 2B).
3.4. Hematological variables and viral load
We did not ﬁnd any correlation between the values of the
hematological variables and viral load: hemoglobin concentration
(r = 0.18), neutrophil count (r = 0.09), and platelet count
(r = 0.05) (data not shown). However, as expected, an undetect-
able viral load was more frequently observed in the group ofFigure 2. (A) Neutrophil and (B) platelepatients with CD4 cells >200/ml (75%) than in the group with CD4
cells < 200/ml (37%) (p < 0.0001).
3.5. Hemoglobin concentration and use of ZDV
Mean hemoglobin concentrations were 13.60  2.35 g/dl for the
group of patients using ZDV regularly (404/700, 57.7%) and
13.65  2.00 g/dl for the group that did not use ZDV (296/700,
42.3%) (p = 0.59).
3.6. Anemia and co-infection with HCV
A total of 113 (16.1%) patients had a co-infection with HCV; 44
(38.9%) of them had anemia. Five hundred and eighty-eight (83.9%)
patients did not have a co-infection with HCV, of whom 233
(39.6%) had anemia (p = 0.9167).
3.7. Anemia and survival
The groups of patients with low CD4 cells (180/701; 25.7%) and
high CD4 cells (521/701; 74.3%) were further divided according to
hemoglobin level. The patients whose hemoglobin concentration
was less than the median value had a higher death rate after 1 year
of follow-up than those whose hemoglobin concentration was on
or above the median value, both in the low CD4 group (14 vs. 4
deaths, p = 0.013) and in the high CD4 group (8 vs. 1 death,
p = 0.0158). Only six of 22 (27.3%) anemic patients who died were
receiving vitamin supplementation (folate or vitamin B12).
Infection was the cause of death in all eight anemic patients with
CD4 200/ml.
4. Discussion
The pathogenesis of anemia, neutropenia, and thrombocytope-
nia in HIV-infected patients is not fully understood, but is assumed
to be multifactorial.16 Anemia can occur at any phase of HIV
infection and its prevalence and severity are correlated with
progression of the disease.11 The prevalence of anemia in our
patients, deﬁned as a hemoglobin concentration of less than 12 g/
dl for women and 14 g/dl for men, was 37.7%, a value somewhat
lower to that found by others.12 Possible explanations for this
ﬁnding could be the good adherence of our patients to medical
follow-up and treatment (more than 80% of patients regularly
using HAART drugs), and improvements in social and nutritional
conditions that have occurred in Brazil, especially in our state, over
recent decades. As expected, patients from the group with low CD4
counts presented a signiﬁcantly increased rate of anemia
compared to patients from the group with high CD4 countst counts according to CD4 groups.
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prevalence of anemia between women (33.1%) and men (40.5%)
(p = 0.0544). This result is in contrast with that found by others,
who have observed a higher prevalence of anemia in women,21
who are more liable to iron deﬁciency. However, in accordance
with the above-mentioned reference, we did ﬁnd a higher
proportion of microcytic anemia in female patients, which could
perhaps be explained by a higher propensity of this group of
patients to have iron deﬁciency.
Furthermore, we did not observe any relationship between
hemoglobin levels and the regular use or not of ZDV, a ﬁnding that
differs from that obtained by others.22 However, as mentioned
above, all our patients were being treated with a HAART regimen;
this could have to a certain degree counteracted the negative
effects of ZDV on erythropoiesis. Others have shown that the use of
ZDV is not associated with anemia when it is part of a HAART
regimen.14 Besides, at our institution, during the study period, ZDV
was suspended as soon as anemia or a decrease in hemoglobin
concentration was detected. Also, we did not observe any
association between co-infection with HCV and anemia.
The mean neutrophil count was lower in the group of patients
with low CD4 cell counts, a ﬁnding that is in accordance with the
literature.16,18 Similar results have been found for platelets.
Patients with a more severe disease (CD4 <200/ml) presented a
slightly lower platelet count. However, the difference between the
two groups was of a lesser magnitude than that observed for
neutrophils. This ﬁnding suggests that platelet level is not the most
reliable surrogate marker for disease progression. It is known that a
substantial percentage of patients present thrombocytopenia as
the ﬁrst clinical manifestation of HIV infection, when it is not
expected until there is a signiﬁcant degree of immunodeﬁciency.23
Finally, as expected, hemoglobin concentration was found to be
a reliable predictor factor for disease progression. Patients with
lower hemoglobin concentrations, irrespective of the CD4 count
group, had a higher death rate after 1 year of follow-up, a ﬁnding
that is in accordance with previous reports.24–27 This ﬁnding
conﬁrms that hemoglobin concentration could be used as a reliable
biomarker of the prognosis in HIV-infected patients, and that a
therapeutic approach is imperative for patients with anemia.
In conclusion, in this study we found an association between
CD4 count and hemoglobin level, neutrophil count, and platelet
count. However, we did not observe any correlation between these
variables and viral load. Moreover, hemoglobin concentration was
strongly correlated with death rates for patients with both low and
high CD4 counts, which warrants the use of this variable as a
predictor factor for the prognosis, especially in countries with
limited resources where routine enumeration of CD4 cells may not
be feasible.
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